LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in November 2021.
AASLD The Liver Meeting (virtual)
Date: November 12-15, 2021
Poxel will present a poster entitled: “FIB-4 score as a predictive factor of advanced liver fibrosis should be adapted according to type 2 diabetes status: screening data from DESTINY-1 (PXL065) phase 2 study.”
Jefferies London Healthcare Conference (in-person and virtual)
Date: November 16-19, 2021
Poxel management team members will be available for one-to-one in-person meetings on November 16-17, 2021, and for virtual meetings on November 18, 2021.
Thomas Kuhn, CEO, will present on November 16, 2021 at 1:00pm GMT / 8:00 am ET.
5th Annual NASH Summit (virtual)
Date: November 29 - December 2, 2021
David Moller, Executive Vice President, Chief Scientific Officer (CSO), will participate and present at this conference.
As part of increasing its focus on rare diseases and on X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies, Poxel will also be represented at the following events:
ALD Connect Annual Meeting (virtual)
Date: November 12-13, 2021
David Moller, Executive Vice President, Chief Scientific Officer (CSO), will participate and present at this conference Poxel programs targeting adrenoleukodystrophy (ALD).
Alex The Leukodystrophy Charity Digital Community Weekend 2021 (virtual)
Date: November 20-21, 2021
David Moller, Executive Vice President, Chief Scientific Officer (CSO), will present Poxel programs targeting adrenoleukodystrophy (ALD).
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.